Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|December 12, 2016
Genomic Analysis of CALGB 40601 for HER2-Positive Breast Cancer
Author(s)Maki Tanioka, MD, PhD
Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger Comprehensive Cancer Center, discusses an integrated analysis of multidimensional genomic data on the phase III CALGB 40601 (Alliance) study, which explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib for patients with HER2-positive breast cancer,
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5